Physical Stability of Amorphous Formulations

More documents

Recommendations

Info

Replacement of SEDDS w/ Solid Dispersion Kaletra Solid Dispersion by Hot-melt Extrusion Kaletra(Lopinavir/Ritonavir, Abbott) ‣ SEDDS(Ritonavir as CYP inhibitor) ‣ Twice daily、3 capsules for each 2.1 cm ‣ Amorphous solid dispersion ‣ Twice daily、2 tablets for each ‣ Refrigeration => Ambient storage condition 1.9 cm
Amorphous Formulation Feature of Amorphous Formulation ‣ Enhances dissolution rate of poorly soluble drugs ‣ Can be administered as small tablets or capsules ‣ Concerns on physical/chemical stability, manufacturing
Page 1 and 2: Physical Stability of Amorphous For
Page 3: Case Study of Liquid-filled Capsule
Page 7 and 8: Heat Flow (W/g) Heat Flow (W /g) Is
Page 9 and 10: Memory before Amorphization Cryo-mi
Page 11 and 12: Miscibility of Amorphous Formulatio
Page 13 and 14: Heat Flow (Exotherm Up) Melting Poi
Page 15 and 16: Heat Flow (Exotherm Up) Time-depend
Page 17 and 18: Heat Flow Relationship b/w Phase Se
Page 19 and 20: Relationship b/w Relaxation & Cryst
Page 21 and 22: Preclinical Development Timeline
Page 23 and 24: Electrospray Deposition Electrospra
Page 25 and 26: Coaxial Electrospray Coaxial electr
Page 27: Acknowledgements National Institute

Physical Stability of Amorphous Formulations

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?